Table 1.
Inhibitory concentration 50% for a broad panel of HCV-specific MABs against H77, J6, and S52 with and without HVR1
| Inhibitory concentration 50% (μg/ml) |
|||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Virus stock titers |
MAb Specificity |
J6.36 | CBH4G antigenic |
CBH5 antigenic |
CBH7 antigenic |
HC84.26 antigenic |
HC33.4 antigenic |
AR1B | AR2A | AR3A | AR4A | AR5A | IGH520 | IGH526 | |||
| Virus | Infectivity* | HCV RNA** | Spec. Inf.*** | HVR1 | Domain A | Domain B | Domain C | Domain D | Domain E | AR1B | AR2A | AR3A | AR4A | AR5A | E1 | E1 | |
| H77 | 4.1 | 7.3 | 0.00066 | - | >50 | >50 | >50 | 0.16 | 0.52 | >50 | 2.1 | 1.2 | 1.0 | 0.38 | >50 | >50 | |
| H77ΔHVR1 | 3.1 | 6.3 | 0.00063 | - | >50 | 9.3 | 0.68 | 0.0040 | 1.8 | 2.8 | 0.013 | 0.012 | 0.0030 | 0.0082 | 0.16 | 1.0 | |
| J6 | 5.1 | 7.6 | 0.0035 | 2.9 | >50 | 16 | >50 | 0.59 | 7.6 | >50 | >50 | 4.9 | 3.7 | 8.1 | >50 | >50 | |
| J6ΔHVR1 | 4.7 | 7.3 | 0.0027 | >50 | >50 | 0.035 | 2.4 | 0.0053 | 1.0 | >50 | 0.032 | 0.0093 | 0.0037 | 0.010 | 0.047 | 0.094 | |
| S52 | 4.4 | 7.6 | 0.00061 | - | >50 | >50 | >50 | 6.7 | 16 | >50 | >50 | >50 | 34 | >50 | >50 | >50 | |
| S52ΔHVR1 | 4.2 | 7.4 | 0.00065 | - | >50 | 0.042 | 2.3 | 0.0033 | 5.7 | >50 | 0.055 | 0.019 | 0.00094 | 2.3 | 0.11 | 0.11 | |
Data was generated by dose-response FFU reduction assays. IC50-values were calculated by four-parameter non-linear curve regression using Graphpad PRISM (v4.03).
*
Infectivity titer given in log10 50% tissue culture infectious dose (TCID50)/ml.
**
HCV RNA titer given in log10 international units (IU)/ml.
***
Specific infectivity given in TCID50/IU.